Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The fight against osteoarthritis (OA) is on at the Kennedy Institute’s Centre for Osteoarthritis Pathogenesis. We have been awarded two research grants looking at different aspects of OA with the ultimate aim of developing novel treatments for this painful and disabling condition.

OA is the most common type of arthritis in the UK, causing the joints to progressively become painful and stiff and making everyday tasks very difficult for patients. When a joint develops osteoarthritis, the cartilage on the end of the bone gradually roughens and becomes thin, whilst the bone underneath thickens.

Osteoarthritis is also the biggest healthcare challenge in rheumatology as there are no effective treatments available; patients rely on painkillers and eventually joint replacement surgery.  

Professor Tonia Vincent, lead researcher for both projects says of the awards: “These two projects are deeply embedded within our OAPathogenesis Centre and will help to stratify patients for future clinical trials and to identify novel therapeutic targets’”

Cartilage repair.

In collaboration with researchers at Utrecht University, this innovative study will look to validate novel markers of cartilage repair in OA patients, paving the way for a potential powerful, cheap, and acceptable treatment for many with advanced OA.

New evidence suggests that osteoarthritic cartilage is able to repair itself if the adverse mechanical environment of the joint is corrected; this has a significant and sustained improvement in pain, but also on cartilage ‘re-growth’. Researchers have identified molecules – biomarkers – that are activated following joint injury and likely drive repair responses, in mouse models. Identifying these biomarkers of successful repair in OA patients has the potential to change the way we view disease, empower patients into believing that their disease is modifiable and open up new possibilities for cheaper, globally applicable treatments.

Project title: Identifying markers in the synovial fluid of patients with osteoarthritis (OA) that predict their ability to repair cartilage
Funder: Arthritis Research UK Project Grant

 

Novel non-invasive imaging method.

The team at the Kennedy Institute, led by Professor Tonia Vincent and Dr Ngee Han Lim, will work to develop a novel imaging agent that can be combined with microCT scanning to create a sensitive, quantitative cartilage assessment tool in OA.

Investigating the pathways that cause OA has been very challenging as the human condition is very variable in its course, it is difficult to obtain tissues from patients and we currently have no way of detecting early disease. In this context, animal models of OA have significant utility because disease can be studied at all stages of the condition, tissues are readily available, and the onset of disease is known.

Evaluation of joint damage both in clinic and in animal models of OA is hampered by the inability to image cartilage accurately and non-invasively. A non-invasive imaging method that would be able to visualise the degradation of cartilage over time would greatly reduce the numbers of animals being used in arthritis research, as well as being potentially translatable into a clinical imaging agent for early OA in humans.

Project title: Development of novel imaging agents for the prospective quantification of joint damage to reduce animal numbers is osteoarthritis research
Funder: NC3Rs – National Centre for the Replacement, Refinement & Reduction of Animals in Research

Similar stories

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.